CBER/CDER Reorganization Will Lengthen Reviews, Ex-FDAer Warns HHS
Executive Summary
FDA's proposed transfer of therapeutic biological product reviews to the Center for Drug Evaluation & Research could lead to longer review times due to decreased emphasis on staff research, a former Center for Biologics Evaluation & Research division director told HHS
You may also be interested in...
CBER-CDER Transition: FDA Creating Template For Product Review Transfer
FDA is creating a template to help it decide what products should be transferred from the Center for Biologics Evaluation & Research to the Center for Drug Evaluation & Research under its proposed reorganization
CBER-CDER Transition: FDA Creating Template For Product Review Transfer
FDA is creating a template to help it decide what products should be transferred from the Center for Biologics Evaluation & Research to the Center for Drug Evaluation & Research under its proposed reorganization
Biologics Approval Record Is “Excellent” Under PDUFA, FDA Says
The Center for Biologics Evaluation & Research's new product review performance has been "excellent" under the user fee program, FDA said